Vertex receives australian tga approval for trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to treat people with cystic fibrosis ages 12 years and older who have at least one f508del mutation

London--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that the australian therapeutic goods administration (tga) has approved the use of trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for people with cystic fibrosis (cf) ages 12 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene, the most common cf-causing mutation worldwide. up to 90% of people living with cf worldwide h
VRTX Ratings Summary
VRTX Quant Ranking